| Old | New | Differences | |
|---|---|---|---|
| 1 | 1 | ||
| 2 | 2 | ||
| 3 | 3 | LCO No. 826 1 of 1 | |
| 4 | 4 | ||
| 5 | 5 | General Assembly Proposed Bill No. 641 | |
| 6 | 6 | January Session, 2021 | |
| 7 | 7 | LCO No. 826 | |
| 8 | 8 | ||
| 9 | 9 | ||
| 10 | 10 | Referred to Committee on GENERAL LAW | |
| 11 | 11 | ||
| 12 | 12 | ||
| 13 | 13 | Introduced by: | |
| 14 | 14 | SEN. LOONEY, 11 | |
| 15 | 15 | th Dist. | |
| 16 | 16 | ||
| 17 | 17 | ||
| 18 | 18 | ||
| 19 | 19 | ||
| 20 | 20 | ||
| 21 | 21 | AN ACT REQUIRING MANUFACTURERS OF BRAND -NAME | |
| 22 | 22 | PRESCRIPTION DRUGS TO PROVIDE SAMPLES OF SUCH DRUGS | |
| 23 | 23 | TO MANUFACTURERS OF GENERIC PRESCRIPTION DRUGS. | |
| 24 | 24 | Be it enacted by the Senate and House of Representatives in General | |
| 25 | 25 | Assembly convened: | |
| 26 | 26 | ||
| 27 | 27 | That the general statutes be amended to require brand-name 1 | |
| 28 | 28 | prescription drug manufacturers to sell sufficient samples to generic 2 | |
| 29 | 29 | drug manufacturers. 3 | |
| 30 | 30 | Statement of Purpose: | |
| 31 | 31 | To promote competition in the prescription drug market by allowing | |
| 32 | 32 | developers of generic drugs and biosimilar products to obtain reference | |
| 33 | 33 | samples. |